UiPath (NYSE:PATH) Price Target Cut to $13.00 by Analysts at Wells Fargo & Company

UiPath (NYSE:PATH) had its price objective trimmed by Wells Fargo & Company from $15.00 to $13.00 in a research report report published on Wednesday, Benzinga reports. The brokerage currently has an equal weight rating on the healthcare company’s stock.

PATH has been the topic of several other reports. Evercore ISI upped their price objective on shares of UiPath from $13.00 to $16.00 and gave the stock an “in-line” rating in a research report on Friday, September 6th. Barclays raised their price target on UiPath from $14.00 to $15.00 and gave the company an “equal weight” rating in a research report on Friday, September 6th. Royal Bank of Canada restated a “sector perform” rating and issued a $16.00 price objective on shares of UiPath in a report on Friday, September 6th. Morgan Stanley reissued an “equal weight” rating and issued a $15.00 price target on shares of UiPath in a research note on Friday, September 6th. Finally, BMO Capital Markets raised their price objective on UiPath from $14.00 to $15.00 and gave the company a “market perform” rating in a research note on Friday, September 6th. Sixteen investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, UiPath currently has an average rating of “Hold” and a consensus price target of $17.47.

UiPath Price Performance

Shares of NYSE:PATH opened at $12.06 on Wednesday. The company has a market cap of $6.91 billion, a price-to-earnings ratio of -75.38 and a beta of 0.88. UiPath has a one year low of $10.37 and a one year high of $27.87. The firm has a fifty day moving average price of $12.46 and a two-hundred day moving average price of $14.24.

UiPath (NYSE:PATH) last posted its quarterly earnings data on Thursday, September 5th. The healthcare company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.01. The company had revenue of $316.00 million during the quarter, compared to analyst estimates of $303.69 million. UiPath had a negative return on equity of 3.98% and a negative net margin of 8.13%. The firm’s quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.09) earnings per share. Equities research analysts expect that UiPath will post -0.23 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Ashim Gupta sold 47,671 shares of the stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $12.07, for a total value of $575,388.97. Following the completion of the transaction, the chief financial officer now owns 849,917 shares of the company’s stock, valued at approximately $10,258,498.19. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 22.37% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Global Financial Private Client LLC increased its stake in shares of UiPath by 9.3% during the first quarter. Global Financial Private Client LLC now owns 6,471 shares of the healthcare company’s stock valued at $144,000 after purchasing an additional 551 shares in the last quarter. Principal Financial Group Inc. increased its position in UiPath by 1.7% during the 1st quarter. Principal Financial Group Inc. now owns 36,772 shares of the healthcare company’s stock valued at $834,000 after buying an additional 622 shares in the last quarter. Advisors Asset Management Inc. raised its stake in UiPath by 35.0% during the first quarter. Advisors Asset Management Inc. now owns 3,037 shares of the healthcare company’s stock valued at $69,000 after buying an additional 787 shares during the last quarter. Empowered Funds LLC boosted its holdings in UiPath by 10.5% in the first quarter. Empowered Funds LLC now owns 10,856 shares of the healthcare company’s stock worth $246,000 after acquiring an additional 1,033 shares in the last quarter. Finally, ORG Partners LLC grew its stake in shares of UiPath by 875.6% in the first quarter. ORG Partners LLC now owns 1,239 shares of the healthcare company’s stock worth $27,000 after acquiring an additional 1,112 shares during the last quarter. 62.50% of the stock is owned by hedge funds and other institutional investors.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.